We have recently reported that treatment with gemcitabine, a potent chemotherapeutic agent and radiation sensitizer, stimulates phosphorylation of the epidermal growth factor receptor (EGFR). Because phosphorylation of EGFR is known to precede receptor degradation, we hypothesized that gemcitabine treatment may also result in EGFR degradation. In two human head and neck cancer cell lines, UMSCC-1 and UMSCC-6, we demonstrated an approximately 80% decrease in total EGFR levels at 72 h after a 2-h treatment with 1 lM gemcitabine. Neither cisplatin nor 5-fluorouracil, which are used to treat head and neck cancer, caused EGFR degradation. EGFR downregulation did not occur at the level of transcription, as assessed by reverse transcription-polymerase chain reaction (RT-PCR), but instead occurred via phosphorylation and ubiquitination of the receptor along a proteosome/lysosome-mediated pathway. Inhibition of EGFR degradation, by either pretreatment with the EGFR tyrosine kinase inhibitor gefitinib or by exposure to the proteosome/lysosome inhibitor MG132, significantly reduced gemcitabine-induced cell death. These results suggest that EGFR degradation may be a novel mechanism for gemcitabine-mediated cell death. These findings also indicate that caution should be exercised when combining gemcitabine with agents that may prevent EGFR degradation, such as EGFR tyrosine kinase inhibitors administered in a suboptimal sequence or proteosome inhibitors.
Introduction
In the treatment of advanced head and neck cancer, the combination of radiation with concurrent chemotherapy has been convincingly shown to be superior to radiation alone and is now accepted as the standard of care (Pignon et al., 2000) . Although cisplatin is the most widely used drug, another promising chemotherapeutic agent is the deoxycytidine analog gemcitabine. We have previously established that gemcitabine is an effective radiosensitizer and cytotoxic agent for squamous cell carcinomas of the head and neck in both preclinical and clinical studies (Shewach and Lawrence, 1996; Eisbruch et al., 2001; Lawrence et al., 2001) . However, the efficacy of chemoradiotherapy is limited by increased, and often prohibitive, toxicity encountered with dose escalation (Eisbruch et al., 2002) .
Targeted inhibitors of the epidermal growth factor receptor (EGFR) have been developed with the goal of improving treatment while minimizing toxicity. EGFR is overexpressed in 80-90% of squamous cell carcinomas of the head and neck (Grandis and Tweardy, 1993) . High tumor EGFR levels have been associated with aggressive clinical features, including decreased survival, decreased radiosensitivity and increased risk of recurrence (Rubin Grandis et al., 1998; Ang et al., 2002; Pomerantz and Grandis, 2004) . EGFR activation results in the initiation of key intracellular signaling pathways that promote malignant behaviors, including cell cycle progression, proliferation and survival (Yarden and Sliwkowski, 2001; Mendelsohn and Baselga, 2003) . Although monotherapy with EGFR inhibitors has met with only limited success (Cohen et al., 2003; Soulieres et al., 2004) , the combination of EGFR inhibitors with radiation therapy or cytotoxic chemotherapy is more promising in head and neck cancer, augmenting response rates and survival (Baselga et al., 2005; Bonner et al., 2006) .
Given the effectiveness of chemoradiotherapy and the promise of EGFR inhibitors, there has been increasing interest in combining these treatments. The potential of this combination therapy has been highlighted in several studies, including a recent study in which we combined gemcitabine with gefitinib, a small molecule EGFR tyrosine kinase inhibitor, in the treatment of head and neck cancer cells and xenografts (Chun et al., 2006) . In this study, we demonstrated that a sequence-specific treatment with gemcitabine preceding gefitinib exposure resulted in massive apoptosis in vitro and significant tumor regression in vivo. We also discovered that exposure to gemcitabine alone resulted in an initial increase in EGFR phosphorylation.
These findings led us to further explore the effects of gemcitabine on EGFR. Although EGFR activation is usually associated with cell survival, receptor phosphorylation can also result in its degradation (Waterman and Yarden, 2001) . Because gemcitabine induced substantial apoptosis in the head and neck cancer cell lines used in our study (Chun et al., 2006) , we hypothesized that gemcitabine treatment may result in EGFR downregulation.
In this study, we investigated the effects of gemcitabine on EGFR levels in two head and neck cell lines, UMSCC-1 and UMSCC-6. Upon discovering that gemcitabine induces downregulation of EGFR, we used immunoblot analysis to characterize the time course and dose dependence of this observation. We next examined if other cytotoxic drugs commonly used to treat head and neck cancer induce this phenomenon. We subsequently determined the role of transcriptional inhibition in the gemcitabine-induced decrease in total EGFR levels. Because the epidermal growth factor induces EGFR degradation via receptor phosphorylation and ubiquitination along a proteosome/lysosome-mediated pathway (Felder et al., 1990; Levkowitz et al., 1998; Yarden and Sliwkowski, 2001) , we studied the role of these receptor modifications and trafficking pathways in gemcitabine-mediated EGFR downregulation. Finally, we studied the effects of blocking EGFR downregulation on gemcitabine-induced cell death.
Results

Gemcitabine causes EGFR downregulation
We began by examining the levels of total and phosphorylated EGFR (pEGFR) in UMSCC-1 and UMSCC-6 cells following gemcitabine treatment (Figure 1a ). For our initial studies, we used a 2-h treatment with 1 mM gemcitabine to simulate clinical dosing of this drug, as previous phase I and II clinical trials on gemcitabine pharmokinetics (Abbruzzese et al., 1991) and infusion duration (Tempero et al., 2003) have demonstrated that micromolar concentrations are safely achievable in the plasma for 2 h or longer. These treatment conditions resulted in increased phosphorylation of EGFR in both cell lines, beginning within the first hour in UMSCC-1 cells and approximately 6-12 h after drug exposure in UMSCC-6 cells. Twenty-four hours after treatment, pEGFR levels had increased by 3.3 (70.6)-and 4.4 (71.0)-fold compared with control in UMSCC-1 and UMSCC-6 cells, respectively (Pp0.01 for both) (Figure 1b) . Increased EGFR phosphorylation persisted until 48 h post-treatment in both cell lines. Levels of total EGFR remained relatively stable initially, but began to decrease at 24-36 h following gemcitabine exposure (Figure 1a ). Significant decreases in total EGFR were seen at 48-72 h, correlating with loss of pEGFR signal. By 72 h after gemcitabine treatment, there was loss of approximately 80% of the total EGFR levels compared with control samples in both cell lines (Pp0.01) (Figure 1b) .
We next determined the dose-response characteristics of gemcitabine-induced EGFR degradation and analysed the effects of decreased EGFR levels on downstream signaling molecules. In UMSCC-1 cells, EGFR downregulation occurred after a 2-h treatment with 100 nM gemcitabine. Increasing the concentration to 1 mM increased neither the rapidity nor the extent of degradation. No effect was seen with 10 nM gemcitabine ( Figure 1c) . Downregulation of EGFR at 72 h was accompanied by inactivation of downstream effectors, including phosphorylated AKT (pAKT) and phosphorylated extracellular signal-regulated kinase (pERK). Poly (ADP-ribosome) polymerase (PARP) cleavage occurred 48-72 h after gemcitabine treatment, correlating with EGFR downregulation. Levels of total AKT and total extracellular signal-regulated kinase (ERK) stayed relatively constant, suggesting that EGFR degradation did not represent a general loss of signaling molecules. A similar pattern was observed in UMSCC-6 cells, with a greater loss of total EGFR, pEGFR and pAKT levels at 48 h compared with corresponding levels in UMSCC-1 cells (Figure 1d ). Taken together, these data demonstrated that gemcitabine induced an increase in pEGFR, followed by downregulation of the EGFR and its downstream signaling cascade in a time-and dose-dependent manner.
EGFR downregulation is specific to gemcitabine
We also examined if EGFR is downregulated by cisplatin and 5-fluorouracil (5-FU), two other drugs used to treat head and neck cancer clinically. Using clonogenic survival assays in UMSCC-1 cells, we determined that 10 mM cisplatin for 2 h or 75 mM 5-FU for 24 h yielded an approximately equivalent degree of clonogenic death as 100 nM gemcitabine for 2 h, a dose which decreases EGFR levels ( Figure 2a ). Equitoxic doses of cisplatin and 5-FU did not downregulate EGFR and resulted in less apoptosis compared with gemcitabine ( Figure 2b ). These findings suggested that EGFR downregulation was not a general result of treatment with cytotoxic chemotherapy.
Gemcitabine-triggered EGFR downregulation is not due to transcriptional inhibition
To determine if gemcitabine decreased total EGFR levels via transcriptional regulation, we used quantitative real-time polymerase chain reaction (PCR) to measure EGFR mRNA levels after gemcitabine treatment. In fact, there was an initial increase in EGFR mRNA levels at 24 h after gemcitabine treatment, reaching 2.3-fold (Pp0.01) in UMSCC-1 cells and 3.7-fold in UMSCC-6 cells (Pp0.01) (Figure 3 ). At 48 and 72 h after gemcitabine treatment, EGFR mRNA levels returned to control levels. ERK1 mRNA levels were measured as an additional control and demonstrated no significant changes following gemcitabine treatment. These findings suggested that gemcitabine-triggered EGFR downregulation is not due to transcriptional inhibition.
Gemcitabine induces EGFR degradation via phosphorylation and ubiquitination along a proteosome/ lysosome-mediated pathway We next investigated the role of receptor modifications in gemcitabine-mediated EGFR downregulation. Pretreatment with 3 or 10 mM gefitinib, an EGFR tyrosine kinase inhibitor, blocked gemcitabine-induced EGFR phosphorylation in UMSCC-1 cells ( Figure 4a and data not shown). Inhibition of EGFR phosphorylation prevented gemcitabine-induced receptor loss. Using co-immunoprecipitation, we determined that EGFR is ubiquitinated in response to gemcitabine, starting as early as 2 h after treatment and persisting through 72 h ( Figure 4b ). Similar results were demonstrated in UMSCC-6 cells (data not shown). These findings suggested that gemcitabine downregulated EGFR via receptor degradation in a receptor phosphorylation-and ubiquitination-dependent mechanism.
We then evaluated the effects of MG132, an inhibitor of both proteosomes and lysosomes (Longva et al., 2002) , on gemcitabine-induced EGFR degradation. We discovered that treatment with MG132 reduced gemcitabine-mediated EGFR degradation in a concentration-dependent manner in UMSCC-1 cells (Figure 4c ). Similar results were demonstrated in UMSCC-6 cells (data not shown). Exposing cells to MG132 in combination with gemcitabine reduced decreases in pEGFR and pAKT, as well as PARP cleavage (Figure 4c) .
We subsequently used immunofluorescence to localize EGFR during the degradation process (Figure 4d ). EGFR was found primarily on the plasma membrane in control cells. Gemcitabine induced EGFR internalization, with subsequent trafficking of the receptor to lysosomes (as demonstrated by co-localization of EGFR and the lysosomal marker LAMP-2), followed by disappearance of EGFR. MG132 prevented gemcitabineinduced EGFR degradation, resulting in accumulation Figure 1 Effect of gemcitabine on EGFR and downstream signaling molecules. (a) UMSCC-1 (top) and UMSCC-6 (bottom) cells were exposed to 1 mM gemcitabine for 2 h, washed with PBS and incubated in drug-free media. At various time points during and after gemcitabine treatment, samples were harvested and immunoblotted for total EGFR, pEGFR and GAPDH (as a loading control). (b) Levels of total and pEGFR after gemcitabine treatment were quantitated, as described in Materials and methods. Each bar graph represents the average of at least four separate experiments. An asterisk indicates statistical significance (Pp0.05) compared to control. (c) UMSCC-1 and (d) UMSCC-6 cells were incubated in various concentrations of gemcitabine for 2 h, and were harvested at the indicated time points and immunoblotted for total and phosphorylated EGFR, AKT and ERK, as well as PARP and GAPDH (used as a loading control).
of EGFR in the lysosomes at 72 h after treatment. These results demonstrated that gemcitabine-mediated EGFR degradation occurs via receptor phosphorylation and ubiquitination along a proteosome/lysosome-mediated pathway.
Blockade of EGFR degradation reduces gemcitabinemediated clonogenic death
Having shown that gemcitabine-mediated EGFR degradation could be reduced by prevention of receptor phosphorylation or inhibition of proteosome/lysosome function, we determined if blocking EGFR degradation protected cells from gemcitabine-induced clonogenic cell death. Pretreatment of UMSCC-1 cells with 3 or 10 mM gefitinib for 24 h reduced gemcitabine-mediated cell death more than fourfold (Figure 5a ). Similar protection from gemcitabine-induced clonogenic death was observed in UMSCC-1 cells pre-treated with a relatively low concentration of erlotinib (1 mM) for 2 h before gemcitabine exposure (Figure 5b) . Likewise, inhibition of EGFR degradation by MG132 protected cells from gemcitabine-induced cell death by 8.8-fold (70.8) (using 2.5 mM MG132) (Figure 5c ) and by 13-fold (70.6) (using 5 mM MG132) (both Pp0.01) (data not shown). These findings demonstrated that prevention of EGFR degradation inhibits gemcitabine-induced cytotoxicity.
Caspase inhibition does not affect gemcitabine-induced EGFR degradation EGFR downregulation can occur rapidly following caspase activation, independent of receptor phosphorylation or ubiquitination (He et al., 2003; Zhuang et al., 2003) . Although our results suggested that gemcitabine downregulates EGFR along a different pathway, one which requires receptor phosphorylation and proteosomal/lysosomal processing, we wanted to determine if activated caspase contributed to gemcitabine-triggered EGFR degradation. We used a continuous maximum nontoxic dose of pan-caspase inhibitor ZVAD which reduced gemcitabine-induced PARP cleavage by 2.6-fold without any effect on gemcitabine-induced EGFR degradation (Supplementary Figure 1) . This suggested that gemcitabine-induced EGFR degradation is not a result of activation of caspase and apoptosis, but rather the cause of apoptosis.
Discussion
In this study, we have found that gemcitabine causes EGFR degradation in a time-and dose-dependent manner, and that this degradation is a key event in producing cytotoxicity. EGFR degradation is initiated by receptor phosphorylation and ubiquitination, and proceeds along a proteosomal/lysosomal pathway, similar to the pathway established for EGF-induced EGFR degradation (Felder et al., 1990; Levkowitz et al., 1998; Waterman and Yarden, 2001; Oksvold et al., 2003) (Figure 6 ). Loss of EGFR causes downregulation of the antiapoptotic signal pAKT, leading to apoptosis and PARP cleavage. Prevention of EGFR degradation via inhibition of receptor phosphorylation or blockade of the proteosomal/lysosomal pathway results in the (b) Cells were exposed to concentrations of cisplatin (2 h) or 5-FU (24 h) that were comparable to 100 nM gemcitabine (2 h) in the induction of clonogenic death and were then harvested at the indicated time points and immunoblotted for total EGFR and GAPDH (for a loading control). 
Role of EGFR degradation in gemcitabine cytotoxicity
FY Feng et al Figure 4 Role of receptor phosphorylation, ubiquitination and proteosomal/lysosomal degradation in gemcitabine-induced EGFR downregulation in UMSCC-1 cells. (a) Cells were pre-treated with 10 mM gefitinib for 24 h before a 2-h treatment with 1 mM gemcitabine. Time-matched controls received either only gemcitabine, only gefitinib or no treatment. At the indicated time points after the initiation of gemcitabine, cells were harvested and immunoblotted for total EGFR, pEGFR and GAPDH (for a loading control). (b) Cells exposed to a 2-h treatment with 1 mM gemcitabine were harvested for immunoprecipitation at the indicated time points. Samples were either immunoprecipitated with total EGFR antibody and probed with ubiquitin antibody or vice versa. (c) and (d) Cells exposed to a 2-h treatment with 1 mM gemcitabine were simultaneously treated with 2.5 mM (c, d) or 5 mM MG132 (c). The MG132 exposure lasted for a total of 6 h, beginning 1 h before gemcitabine initiation. Time-matched controls received no MG132 and/or no gemcitabine. At the indicated time points (after the initiation of treatment), samples were immunoblotted (c) for total EGFR, pEGFR, pAKT, total AKT, PARP and GAPDH (for a loading control) or were prepared for immunofluorescent staining (d) using total EGFR antibody (green), LAMP2 (red, a lysosomal marker) antibody and DAPI (blue). Colocalization of antibodies against total EGFR and LAMP2 is reflected as yellow staining.
Figure 5
Effect of blocking EGFR degradation on gemcitabine-mediated clonogenic cell death. Clonogenic survival assays were performed to compare the response of UMSCC-1 cells to gemcitabine alone or in combination with agents blocking EGFR degradation, using the EGFR tyrosine kinase inhibitors gefitinib (a) or erlotinib (b) or the proteosome inhibitor MG132 (c) pretreatment regimens described in Figure 4 . Erlotinib (1 mM) treatment was given for 2 h before gemcitabine treatment.
Role of EGFR degradation in gemcitabine cytotoxicity FY Feng et al inhibition of gemcitabine-mediated clonogenic death. Gemcitabine-induced EGFR degradation does not appear to represent a generalized proteolysis of signal transducing molecules, as total ERK and AKT levels are maintained, and degradation is independent of activation of caspase. Likewise, degradation was not produced upon treatment with cisplatin and 5-FU at equitoxic doses, suggesting that EGFR degradation might not be a generalized response to cytotoxic therapy. Finally, the observed decrease in EGFR is not caused by a decrease in transcription. In fact, there is a transient increase in EGFR transcription at 24 h after gemcitabine treatment; it is possible that this increased transcription may account for why total EGFR protein levels were not significantly decreased until 48-72 h following drug exposure.
To our knowledge, this study provides the first evidence that a conventionally used cytotoxic chemotherapeutic agent can induce specific degradation of EGFR. Although loss of EGFR levels has been demonstrated in response to several agents now in clinical use, the mechanisms of receptor downregulation in response to these drugs differ from that of gemcitabine. For example, retinoic acid and histone deacetylase inhibitors downregulate EGFR via transcriptional inhibition (Rubin Grandis et al., 1996; Chinnaiyan et al., 2005) . In addition, inhibitors of heat shock protein 90 promote EGFR degradation by affecting protein chaperoning and processing (Supino-Rosin et al., 2000) . Recently, theaflavin-3,3 0 -digallate, a derivative from black tea, was demonstrated to trigger EGFR degradation along a proteosome/lysosome pathway, which is independent of receptor phosphorylation (Mizuno et al., 2005) . Several agents, such as ultraviolet A light and singlet oxygen, result in EGFR degradation as a nonspecific target in caspase activation (He et al., 2003; Zhuang et al., 2003) . Of all the agents discussed, only gemcitabine has been demonstrated to induce EGFR degradation along a pathway similar to EGF-induced receptor downregulation. In fact, our findings demonstrate that a conventional chemotherapeutic agent may induce similar results as a targeted EGFR antibody, such as cetuximab (IMC-C225, erbitux).
Based on our results, we propose that EGFR degradation under stressful conditions such as DNA damage induced by gemcitabine may be a mechanism of cell death in head and neck cancers and other tumors dependent on EGFR signaling; whereas a loss of EGFR signal alone may produce only cell cycle arrest. This hypothesis has been indirectly supported by a wide range of laboratory and clinical studies demonstrating modest activity of the EGFR inhibitors as monotherapeutic agents and synergistic response in combination with DNA-damaging agents such as radiation (Mendelsohn and Baselga, 2003) . From a signaling perspective, the relationship between EGFR degradation and cell death is tenable, as loss of EGFR leads to downregulation of pAKT, thus removing an important survival signal and contributing to apoptosis (Cross et al., 2000) . In showing that the prevention of EGFR degradation restores pAKT levels and reduces cell death, our experiments provide further support of this relationship.
One noteworthy finding in our study is the functionality of internalized EGFR. Using immunofluorescent staining, we demonstrated that MG132 treatment prevents gemcitabine-mediated EGFR degradation by causing accumulation of EGFR in lysosomes. Correlative immunoblot experiments revealed that this internalized pool of EGFR continues to signal, as shown by persistent elevation of pEGFR and pAKT levels. Previous studies have demonstrated that internalized EGFR can signal from endosomes (Burke et al., 2001) . There is also additional evidence that, in response to radiation, EGFR can translocate to the nucleus and stimulate DNA repair, and this response is prevented by cetuximab-induced EGFR degradation (Dittmann et al., 2005) . Our study is unique in demonstrating that internalized EGFR can protect tumor cells from a chemotherapeutic cytotoxic insult. Taken together, our results and these findings suggest that, in response to different stimuli, EGFR may be internalized to and remain active in various intracellular compartments. It is important to note the context in which EGFR is internalized, and this area will require further investigation.
There are potential clinical implications to these observations. Our results suggest that one must exercise Figure 6 Proposed model of gemcitabine-induced apoptosis via EGFR degradation. Gemcitabine treatment, through an unknown mechanism, leads to phosphorylation of EGFR, which promotes ubiquitination of the receptor. EGFR is then targeted to proteosomes and lysosomes for degradation, resulting in downregulation of the downstream survival signal pAKT, leading to apoptosis and PARP cleavage. Blocking EGFR degradation at various steps of this pathway with the use of gefitinib or MG132 reduces gemcitabinemediated cell death.
caution in combining gemcitabine with agents that may inhibit EGFR degradation. One class of such agents is proteosome inhibitors, which are currently being investigated in clinical trials for solid tumors (Rajkumar et al., 2005) . Surprisingly, another class of such agents is EGFR tyrosine kinase inhibitors, when combined with gemcitabine in a suboptimal order. Two previous papers have demonstrated that pre-treatment with an EGFR tyrosine kinase inhibitor can limit gemcitabine-induced cell death (Nelson and Fry, 2001; Chun et al., 2006) . Based on our current study, we propose that this protection from cell death results from limitation of EGFR degradation.
Since the focus of this study has been on assessing gemcitabine-induced EGFR degradation, it will be necessary to further characterize the specificity of this observation. In the two cell lines used in this study, EGFR degradation is unique to gemcitabine and does not occur in response to cisplatin or 5-FU. However, both of these cell lines demonstrate relative resistance to cisplatin and 5-FU on clonogenic assays. It is possible that EGFR degradation may occur in other cell lines that are more sensitive to these drugs or in response to other classes of cytotoxic drugs. Moreover, the mechanism by which gemcitabine induces EGFR phosphorylation is presently unknown. One possibility is that gemcitabine-mediated EGFR phosphorylation might be due to activation of c-Src, as gemcitabine induced EGFR phosphorylation at tyrosine 845, which is a known c-Src kinase target (Sato et al., 1995) . This pathway of EGFR activation has been implicated previously in response to cisplatin (Benhar et al., 2002) . On the other hand, it has been shown that phosphorylation of Y1045, which is a cbl binding site, is necessary for ubiquitination of EGFR. Studies using cells expressing specific EGFR mutations, such as at Y1045 (Oksvold et al., 2003) , may allow us to determine the mechanism and significance of EGFR phosphorylation. Although these studies are beyond the scope of this paper, we hope that further investigation in this area will allow us to eventually use EGFR response to gemcitabine for prediction of clinical response in head and neck cancers.
Materials and methods
Cell culture
The human head and neck squamous carcinoma cell lines UMSCC-1 and UMSCC-6 were obtained courtesy of Dr Thomas E Carey (University of Michigan, Ann Arbor, MI, USA). Experimental conditions for cell culture were maintained as described previously (Chun et al., 2006) .
Reagents
Phosphorylated EGFR (Y845), phosphorylated AKT (Ser473), total AKT, phosphorylated ERK (Thr202/Y204), total ERK and PARP antibodies were acquired from Cell Signaling (Danvers, MA, USA). Total EGFR (sc-03) and ubiquitin (sc-8017) antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody was purchased from Abcam (Cambridge, MA, USA). LAMP-2 antibody was acquired from Calbiochem (San Diego, CA, USA).
Drug treatments
Cells were exposed to gemcitabine (Gemzar) (Eli Lilly and Co., Indianapolis, IN, USA) for 2 h, washed with phosphatebuffered saline (PBS), incubated in drug-free media and subsequently harvested at various time points after drug initiation. Gemcitabine treatment was also combined with either the EGFR tyrosine kinase inhibitors gefitinib (Iressa, ZD1839) (AstraZeneca, Macclesfield, Cheshire, UK) or erlotinib (Tarceva) (Genentech Inc., San Francisco, CA, USA) or the proteosomal/lysosomal inhibitor MG132 (Sigma-Aldrich, St Louis, MO, USA) or the pan-caspase inhibitor ZVAD (Biovision, Inc., Mountain View, CA, USA), with time-matched controls performed in the absence of gemcitabine. Treatment with gemcitabine was also compared with cisplatin (Bedford Laboratories, Bedford, OH, USA) and 5-FU (American Pharmaceutical Partners Inc., Schaumburg, IL, USA).
Immunoblotting and immunoprecipitation
Immunoblotting and immunoprecipitation were performed as described previously (Chun et al., 2006) , with only adherent cells harvested for analysis. For quantification of relative protein levels, immunoblot films were scanned and analysed using ImageJ 1.32j software (NIH, Bethesda, MD, USA). Unless otherwise indicated, the relative protein levels shown represent a comparison to untreated controls.
Immunofluorescence
After completion of various drug treatments, cells (on fourwell chamber slides; Nalge Nunc International, Rochester, NY, USA) were fixed in 4% paraformaldehyde at À201C for 10 min, followed by three PBS washes. Cell membranes were permeabilized via incubation in methanol for 10 min. Immunofluorescent staining was then performed as described previously (Chun et al., 2006) .
RNA isolation and quantitative PCR
After cells were harvested in TRIzol (Invitrogen Co., Carlsbad, CA, USA), RNA was extracted and reverse transcribed into cDNA as described previously (Nyati et al., 2004) . Quantitative PCR (QPCR) was then performed using SYBR Green dye on an Applied Biosystems 7300 Real-time PCR system (Applied Biosystems, Foster City, CA, USA) as described previously (Tomlins et al., 2005) . All oligonucleotide primers were synthesized by Integrated DNA Technologies (Coralville, IA, USA). Primers for EGFR (Macabeo-Ong et al., 2002) , and GAPDH and HMBS primers (Tomlins et al., 2005) were as described previously. The forward primer for ERK1 was 5 0 -CAA CAT GAA GGC CCG AAA CTA CC-3 0 and the reverse primer for ERK1 was 5 0 -TAA CAT CCG GTC CAG CAG GTC A AG-3
0 . Approximately equal efficiencies of the primers were confirmed using serial cDNA dilutions. All reactions underwent melt curve analysis, and products from selected experiments were resolved by electrophoresis on 1.5% agarose gels.
Clonogenic survival assays
Twenty-four hours after the initiation of drug treatment, cells were subcultured at clonal density. Clonogenic survival was assessed using a colony formation assay described previously (Lawrence et al., 1992) . The fraction surviving each treatment was normalized to the survival of the control cells. Gemcitabine cell survival curves were fitted using the equation
, where SF is the surviving fraction, C is the gemcitabine concentration, C 50 is the concentration of gemcitabine that produces a 50% cell survival and m is the slope of the sigmoid curve. The effect of gefitinib, erlotinib or MG132 on gemcitabine-induced clonogenic death was calculated by comparing the ratio of the areas under the respective cell survival curves (AUCs).
Statistics
Results are presented as the mean7s.e. of at least three experiments. Student's t-test was used to assess the statistical significance of differences. A significant level threshold of Pp0.05 was used.
